Forschungsverbund Berlin E.v.

Universität Zu Koln

Bayer Aktiengesellschaft

European Molecular Biology Laboratory

Europaisches Laboratorium Molekularbiologie

Hartmut Oschkinat

Ronald Kühne

Luis Serrano

Hans-Günther Schmalz

Matthias Müller

Cedric Reuter

Robert Opitz

Helena Domingues

Walter Sebald

Hans-Guenther Schmalz

Matthias Barone

Peter Huy

David Cregut

Joerg Peters

Ronald Kuehne

Arne Soicke

Christoph Brockmann

Jan Zaminer

Cédric Michael Reuter

The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and/or prevention of tumor metastases.

Inhibitors for inhibiting tumor metastasis

The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

Structural mimetics of proline-rich peptides and use thereof

The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumors.

Structural mimetics of proline-rich peptides and the pharmaceutical use thereof

The invention relates to methods for the stabilisation of cytokines and to cytokines generated by such methods. The methods of the invention involve mutating the amino acid sequence of a cytokine so as to remove solvent-exposed hydrophobic residues, and/or mutating the amino acid sequence of the cytokine so as to stabilise one or more secondary structure elements in the molecule. These steps have the effect of destabilsing intermediates that are formed during the folding process, relative to the stability of the cytokine in its naturally folded state, so increasing the yield of the cytokine as produced in vitro.

Modified cytokine

The design of antagonists of 4-helix bundle cytokine specific receptors, mimetic peptides that are able to act as such antagonists and their use as pharmaceutical agents is disclosed.

Coiled-coil dimer derived antagonists of 4-helix bundle cytokines, design and uses thereof

Growing community of inventors

Berlin, Germany

Hartmut Oschkinat